Hadoux, J., Kanaan, C., Durand, A., Hescot, S., Hautefeuille, V., Cadiot, G., Tauveron, I., Laboureau, S., Do Cao, C., Walter, T., Petorin, C., Blanchet, O., Jannin, A., Gu, C., Faron, M., Leteurtre, E., Rousselet, M., Zakeyh, J. J., Marchal, A., Chatelain, D., Beaulaton, C., Hervieu, V., Ducreux, M., Scoazec, J., & Baudin, E. (2021). prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. European journal of cancer, 152, 100–115. http://access.bl.uk/ark:/81055/vdc_100134863601.0x00002a